Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset

dc.contributor.author
Chua, Winnie
dc.contributor.author
Easter, Christina L.
dc.contributor.author
Guasch i Casany, Eduard
dc.contributor.author
Sitch, Alice
dc.contributor.author
Casadei, Barabara
dc.contributor.author
Crijns, Harry J.G.M.
dc.contributor.author
Haase, Doreen
dc.contributor.author
Hatem Stéphane
dc.contributor.author
Kääb, Stefan
dc.contributor.author
Mont Girbau, Lluís
dc.contributor.author
Schotten, Ulrich
dc.contributor.author
Sinner, Moritz F.
dc.contributor.author
Hemming, Karla
dc.contributor.author
Deeks, Jonathan J.
dc.contributor.author
Kirchhof, Paulus
dc.contributor.author
Fabritz, Larissa
dc.date.issued
2020-05-29T13:56:10Z
dc.date.issued
2020-05-29T13:56:10Z
dc.date.issued
2019-05-21
dc.date.issued
2020-05-29T13:56:11Z
dc.identifier
1471-2261
dc.identifier
https://hdl.handle.net/2445/163120
dc.identifier
698364
dc.description.abstract
Background: Atrial fibrillation (AF) is caused by different mechanisms but current treatment strategies do not target these mechanisms. Stratified therapy based on mechanistic drivers and biomarkers of AF have the potential to improve AF prevention and management outcomes. We will integrate mechanistic insights with known pathophysiological drivers of AF in models predicting recurrent AF and prevalent AF to test hypotheses related to AF mechanisms and response to rhythm control therapy. Methods: We will harmonise and combine baseline and outcome data from 12 studies collected by six centres from the United Kingdom, Germany, France, Spain, and the Netherlands which assess prevalent AF or recurrent AF. A Delphi process and statistical selection will be used to identify candidate clinical predictors. Prediction models will be developed in patients with AF for AF recurrence and AF-related outcomes, and in patients with or without AF at baseline for prevalent AF. Models will be used to test mechanistic hypotheses and investigate the predictive value of plasma biomarkers. Discussion: This retrospective, harmonised, individual patient data analysis will use information from 12 datasets collected in five European countries. It is envisioned that the outcome of this analysis would provide a greater understanding of the factors associated with recurrent and prevalent AF, potentially allowing development of stratified approaches to prevention and therapy management.
dc.format
9 p.
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
BioMed Central
dc.relation
Reproducció del document publicat a: https://doi.org/10.1186/s12872-019-1105-4
dc.relation
BMC Cardiovascular Disorders, 2019, vol. 19, p. 120
dc.relation
https://doi.org/10.1186/s12872-019-1105-4
dc.relation
info:eu-repo/grantAgreement/EC/H2020/633196/EU//CATCH ME
dc.rights
cc-by (c) Chua, Winnie et al., 2019
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Medicina)
dc.subject
Fibril·lació auricular
dc.subject
Terapèutica
dc.subject
Marcadors bioquímics
dc.subject
Atrial fibrillation
dc.subject
Therapeutics
dc.subject
Biochemical markers
dc.title
Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.